pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,833 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT801Endpoints604BioPharma Dive231onclive165Fierce Biotech74BioSpace71raps32globenewswire health20fda press
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • City banks nearly $100M for next-gen RNAi drugs
    Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.
    BioPharma Dive · 1mo ago↗ source
  • Incyte CEO sees $2B Vega deal aiding a post-Jakafi future
    Bill Meury has been in or led the C-suite of several biopharma companies that have constructed multibillion-dollar exits over the past decade: Allergan, Karuna and Anthos. Now, he’s the one buying.…
    Endpoints · 1mo ago↗ source
  • City Therapeutics gets $99M to gather data on three RNAi medicines
    City Therapeutics, the next-gen RNAi startup founded and led by former Alnylam executives, has collected $99.5 million to fund the clinical development of its first three candidates and expand into…
← prev
page 35 of 74
next →
20
fda recalls20
fda medwatch16
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 1mo ago
↗ source
  • Roche stakes $700M on Nurix’s protein-degrading drug
    Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.
    BioPharma Dive · 1mo ago↗ source
  • GoHealth files for bankruptcy, as Medicare Advantage insurers pull back
    The volatile Medicare Advantage market can now count GoHealth as a casualty. GoHealth, a health insurance marketplace focused on seniors, on Sunday voluntarily filed for Chapter 11 bankruptcy in th…
    Endpoints · 1mo ago↗ source
  • Tango data add to growing momentum for pancreatic cancer drugs
    A combination involving Tango’s experimental therapy appeared to boost response rates in a small clinical trial well beyond what would be expected, sparking a share surge.
    BioPharma Dive · 1mo ago↗ source
  • Incyte to buy blood disorder drug in possibly $2B deal
    Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.
    BioPharma Dive · 1mo ago↗ source
  • J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B
    The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.
    BioPharma Dive · 1mo ago↗ source
  • Treeline to go public via reverse merger with Standard BioTools
    Treeline Biosciences has shared plans to debut on public markets through a reverse merger with Standard BioTools in a move that should give the company a cash runway through 2029. The
    Endpoints · 1mo ago↗ source
  • ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
    At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.
    BioPharma Dive · 1mo ago↗ source
  • STAT+: UnitedHealthcare’s lactation billing feud, and fake strokes
    The biggest U.S. health insurer is changing how it pays for lactation counseling, and it could cut payment for many providers.
    STAT · 1mo ago↗ source
  • J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS field
    Johnson & Johnson is making another early-stage oncology deal, dishing out $1 billion in cash to acquire Firefly Bio, a preclinical startup working on degrader antibody conjugates. J&J now joins th…
    Endpoints · 1mo ago↗ source
  • GSK inks multi-target pact with Engitix; Sangamo considers strategic options
    Plus news about Pfizer's latest label expansion. 🤝 GSK inks multi-target liver pact with Engitix: London-based Engitix will use disease models based on its extracellular matrix technology to ident…
    Endpoints · 1mo ago↗ source
  • Tango plans Phase 3 pancreatic cancer study after combo success
    Will 2026 be remembered as the year when pancreatic cancer finally became treatable? Following Revolution Medicines’ smashing success at the annual American Society of Clinical Oncology meeting las…
    Endpoints · 1mo ago↗ source
  • Coming Soon
    Next installments of the biopharma pay series coming soon
    Endpoints · 1mo ago↗ source
  • STAT+: Novo underwhelmed by drug it once fought Pfizer for
    Revolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech news
    STAT · 1mo ago↗ source
  • Biopharma's top-paid CEOs of 2025: 25 making $25M+
    For the first time in four years, Endpoints News is raising the bar for what it means to be a top-paid CEO. The previous floor of $20 million is no longer rich enough. The biopharma ...
    Endpoints · 1mo ago↗ source
  • Cavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugs
    Cavalry Biosciences, the first biotech out of incubator and investor Jupiter Bioventures, is working on a $75 million Series B to bring its first two drug candidates into clinical testing, CEO Pres…
    Endpoints · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
    Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide
    STAT · 1mo ago↗ source
  • #ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shot
    The molecules known as triple-Gs — agonists of GLP-1, GIP and glucagon — are drawing attention as data build suggesting they could be the most effective class of obesity drugs. Eli Lilly is leading…
    Endpoints · 1mo ago↗ source
  • STAT+: J&J spends $1 billion to enter KRAS race for cancer treatments
    Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly buzzy field of KRAS inhibitors.
    STAT · 1mo ago↗ source
  • Major readouts from the annual diabetes conference
    Why "Schedule F" matters, the Ebola outbreak response, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate
    A combination of pancreatic cancer drugs from Tango Therapeutics and Revolution Medicines led to a strong response rate in an early-stage trial.
    STAT · 1mo ago↗ source
  • Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal
    Incyte plans to spend $1.25 billion upfront to buy Star Therapeutics' subsidiary Vega Therapeutics and its Phase 3 bleeding disorder candidate, the companies said Monday. The deal package also incl…
    Endpoints · 1mo ago↗ source
  • Takeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appeal
    Takeda has updated its financial results to reflect costs it could incur after losing an antitrust lawsuit concerning its laxative drug Amitiza. In May, the US District Court in Massachusetts ruled…
    Endpoints · 1mo ago↗ source